News

The amount of RNA molecules present in the blood and central nervous system of amyotrophic lateral sclerosis (ALS) patients seems to play a role in the onset and development of the disease, a study published in the journal Scientific Reports showed. A better understanding of the involvement of RNA molecules…

Increasing the levels of a neurotransmitter-generating brain enzyme that is in short supply in paralysis disorders restored movement in a fly model of ALS, an Italian study shows. Bolstering the Gad1 enzyme’s levels also led to the return of a pre-disease pattern of nerve cell organization, the researchers said. The…

University of North Carolina researchers have identified the DNA sequence in a virus that lets it deliver treatments for neurodegenerative diseases to the brain. The finding may pave the way for the development of improved and safer gene therapies for diseases like ALS, the team said. A number of gene therapies…

David Curtis Glebe, a retired 64-year-old public prosecutor now living in Millsboro, Delaware, knows he’s lucky to be alive. In mid-2013, while in Arizona, Glebe was diagnosed with pancreatic neuroendocrine cancer (PNET) — the same disease that killed Apple’s founder and CEO Steve Jobs. After three years of progress…

Researchers in Germany studying standards of care in amyotrophic lateral sclerosis (ALS) patients found a high unmet need for assistive technology devices. The cohort study, “Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach,” was published in the journal Amyotrophic Lateral Sclerosis and…

Restoring a protein that’s missing in a type of ALS that affects 10 percent of patients stopped nerve cell deterioration, University of Southern California researchers report. The results also applied to a disease called frontotemporal dementia, or FTD, according to the team at USC Stem Cell. Their study, ”Haploinsufficiency leads…

Researchers at Sweden’s University of Gothenburg say low red blood cell count at a young age is a risk factor for amyotrophic lateral sclerosis (ALS). Disease onset was also associated with low muscle strength and low body fat during the later teen years. ”One should never overstate conclusions from a…

UCLA researchers have identified the regulatory network that controls the transformation of neuronal progenitor cells into movement nerve cells in chicken and mouse embryos. The study adds insight into the development and functioning of spinal movement nerve cells. It also may contribute to the production of stem cell-derived movement nerve…

Neuraltus Pharmaceuticals signaled that it was moving toward the analysis stage of a Phase 2 clinical trial of its ALS therapy NP001. The signal was its announcement that it had completed the last patient visit in the study. Neuraltus conducted the trial (NCT02794857) to confirm the results of a…

Neurodegeneration in a subset of amyotrophic lateral sclerosis (ALS) patients is a consequence of abnormal DNA damage responses, a finding that provides new possibilities for therapeutic interventions. About 5 percent of familial amyotrophic lateral sclerosis (fALS), and up to 1 percent of sporadic ALS (sALS), have been linked to mutations in…